Phase IIb Safety and Efficacy Study of Four Dose Regimens of BAY1021189 in Patients With Heart Failure With Reduced Ejection Fraction Suffering From Worsening Chronic Heart Failure (SOCRATES-REDUCED)
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 456 participants.
Also called NCT01951625
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 456 participants
- Sponsor
- Registry
-
NCT01951625 -
2013-002287-11
-
- Main results
- Effect of Vericiguat, a Soluble Guanylate Cyclase Stimulator, on Natriuretic Peptide Levels in Patients With Worsening Chronic Heart Failure and Reduced Ejection Fraction: The SOCRATES-REDUCED Randomized Trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Australia, Austria, Belgium, Bulgaria, Canada, Czechia, Denmark, France, Germany, Greece, Hungary, Israel, Italy, Japan, Netherlands, Poland, Singapore, South Korea, Spain, Sweden, Switzerland, Taiwan, United Kingdom
- Registry status
- Completed
Technical summary
Registry record NCT01951625. Randomized; quadruple masking; primary purpose treatment. Start 2013-11-29 (actual); primary completion 2015-05-14 (actual). Results posted on 2021-03-25.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Phase IIb Safety and Efficacy Study of Four Dose Regimens of BAY1021189 in Patients With Heart Failure With Reduced Ejection Fraction Suffering From Worsening Chronic Heart Failure (SOCRATES-REDUCED)
- Condition
- Heart Failure
- Intervention (Drug)
- Vericiguat (BAY1021189) (1.25 mg)
- Intervention (Drug)
- Vericiguat (BAY1021189) (5 mg)
- Intervention (Drug)
- Placebo
- Lead sponsor
- Bayer
Record details
- Record id
cardio:ct-nct01951625- Content hash
794513dbadb1c49cc741c512d2f203e16b5ec1fde582ed4b914cbb0828d48935